CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

ResMed Q1 FY27 diluted EPS rises 23% year-over-year to $2.92

By Public Technologies
  • ResMed's Q1 FY27 GAAP diluted earnings per share rose 23% year over year to $2.92.
  • Revenue climbed 6% year over year to $1.41 billion, driven primarily by strong demand for sleep devices, masks and accessories.
  • Operating cash flow fell 8% year over year to $422 million, while shareholder returns through repurchases and dividends exceeded $1 billion.
  • The MatrixCare divestiture closed, and the AirTouch F40 fabric CPAP mask launched in the U.S.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ResMed Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk